TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.
Cora Sternberg, MD, FACP, Weill Cornell Medicine
Advertisement
Articles by Cora Sternberg, MD, FACP, Weill Cornell Medicine
Advertisement
Latest Updated Articles
Rapid Readouts: TROPHY-U-01 Cohort 1 Final ResultsOctober 14th 2020
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
3
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
4
The OncFive: Top Oncology Articles for the Week of 5/31
5